ISTH Academy

Create Account Sign In
Histone content, and thus DNA content, is associated with differential in vitro lysis of acute ischemic stroke clots
Author(s): ,
Matthew T. Bender
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
Matthew T. Bender, Department of Neurosurgery, University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA.
,
Craig N. Morrell
Affiliations:
Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, New York, USA
,
Kevin Welle
Affiliations:
Mass Spectrometry Resource Laboratory, University of Rochester Medical Center, Rochester, New York, USA
,
Thomas K. Mattingly
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Tarun Bhalla
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Aditya Gunturi
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Logan Worley
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Siddharth Chittaranjan
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Derrek A. Schartz
Affiliations:
Department of Imaging Sciences, University of Rochester Medical Center, Rochester, New York, USA
,
Clifton Houk
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Gurkirat S. Kohli
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Nathaniel R. Ellens
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
,
Redi Rahmani
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
Sajal Medha K. Akkipeddi
Affiliations:
Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York, USA
ISTH Academy. 05/01/24; 422464
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

You may also access ISTH content "anytime, anywhere" with the FREE ISTH Academy App for iOS and Android.
Journal Abstract
Discussion Forum (0)
Rate & Comment (0)
Background

Fibrin, von Willebrand factor, and extracellular DNA from neutrophil extracellular traps all contribute to acute ischemic stroke thrombus integrity.

Objectives

In this study, we explored how the proteomic composition of retrieved thromboemboli relates to susceptibility to lysis with distinct thrombolytics.

Methods

Twenty-six retrieved stroke thromboemboli were portioned into 4 segments, with each subjected to 1 hour of in vitro lysis at 37 °C in 1 of 4 solutions: tissue plasminogen activator (tPA), tPA + von Willebrand factor–cleaving ADAMTS-13, tPA + DNA-cleaving deoxyribonuclease (DNase) I, and all 3 enzymes. Lysis, characterized by the percent change in prelysis and postlysis weight, was compared across the solutions and related to the corresponding abundance of proteins identified on mass spectrometry for each of the thromboemboli used in lysis.

Results

Solutions containing DNase resulted in approximately 3-fold greater thrombolysis than that with the standard-of-care tPA solution (post hoc Tukey, P < .01 for all). DNA content was directly related to lysis in solutions containing DNase (Spearman’s ρ > 0.39 and P < .05 for all significant histones) and inversely related to lysis in solutions without DNase (Spearman’s ρ < −0.40 and P < .05 for all significant histones). Functional analysis suggests distinct pathways associated with susceptibility to thrombolysis with tPA (platelet-mediated) or DNase (innate immune system–mediated).

Conclusion

This study demonstrates synergy of DNase and tPA in thrombolysis of stroke emboli and points to DNase as a potential adjunct to our currently limited selection of thrombolytics in treating acute ischemic stroke.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies